PMID- 25989735
OWN - NLM
STAT- MEDLINE
DCOM- 20160406
LR  - 20181113
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 7
IP  - 5
DP  - 2015 May
TI  - Biological ageing and frailty markers in breast cancer patients.
PG  - 319-33
AB  - Older cancer patients are a highly heterogeneous population in terms of global 
      health and physiological reserves, and it is often difficult to determine the 
      best treatment. Moreover, clinical tools currently used to assess global health 
      require dedicated time and lack a standardized end score. Circulating markers of 
      biological age and/or fitness could complement or partially substitute the 
      existing screening tools. In this study we explored the relationship of potential 
      ageing/frailty biomarkers with age and clinical frailty. On a population of 82 
      young and 162 older non-metastatic breast cancer patients, we measured mean 
      leukocyte telomere length and plasma levels of interleukin-6 (IL-6), regulated 
      upon activation, normal T cell expressed and secreted (RANTES), monocyte 
      chemotactic protein 1 (MCP-1), insulin-like growth factor 1 (IGF-1). We also 
      developed a new tool to summarize clinical frailty, designated Leuven 
      Oncogeriatric Frailty Score (LOFS), by integrating GA results in a single, 
      semi-continuous score. LOFS' median score was 8, on a scale from 0=frail to 
      10=fit. IL-6 levels were associated with chronological age in both groups and 
      with clinical frailty in older breast cancer patients, whereas telomere length, 
      IGF-1 and MCP-1 only correlated with age. Plasma IL-6 should be further explored 
      as frailty biomarker in cancer patients.
FAU - Brouwers, Barbara
AU  - Brouwers B
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
FAU - Dalmasso, Bruna
AU  - Dalmasso B
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
AD  - Department of Internal Medicine, Istituto di Ricerca a Carattere Clinico e 
      Scientifico (IRCCS), Azienda Ospedaliera Universitaria (AOU) San Martino Istituto 
      Nazionale Tumori (IST), Genoa, Italy.
FAU - Hatse, Sigrid
AU  - Hatse S
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
FAU - Laenen, Annouschka
AU  - Laenen A
AD  - Interuniversity Centre for Biostatistics and Statistical Bioinformatics, Leuven, 
      Belgium.
FAU - Kenis, Cindy
AU  - Kenis C
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
FAU - Swerts, Evalien
AU  - Swerts E
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
FAU - Neven, Patrick
AU  - Neven P
AD  - Leuven Multidisciplinary Breast Center, University Hospitals Leuven, Belgium.
FAU - Smeets, Ann
AU  - Smeets A
AD  - Leuven Multidisciplinary Breast Center, University Hospitals Leuven, Belgium.
FAU - Schoffski, Patrick
AU  - Schoffski P
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
FAU - Wildiers, Hans
AU  - Wildiers H
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
AD  - Leuven Multidisciplinary Breast Center, University Hospitals Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCL5 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Interleukin-6)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/*blood
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*blood
MH  - Chemokine CCL2/blood
MH  - Chemokine CCL5/blood
MH  - Female
MH  - *Frail Elderly
MH  - Geriatric Assessment/methods
MH  - Humans
MH  - Insulin-Like Growth Factor I/analysis/metabolism
MH  - Interleukin-6/blood
MH  - Middle Aged
MH  - *Telomere
PMC - PMC4468313
OTO - NOTNLM
OT  - biomarkers
OT  - breast cancer
OT  - frailty
OT  - geriatric assessment
OT  - interleukin-6
COIS- Conflict of interest statement None of the authors have potential conflicts of 
      interest to disclose.
EDAT- 2015/05/21 06:00
MHDA- 2016/04/07 06:00
PMCR- 2015/05/01
CRDT- 2015/05/21 06:00
PHST- 2015/05/21 06:00 [entrez]
PHST- 2015/05/21 06:00 [pubmed]
PHST- 2016/04/07 06:00 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
AID - 100745 [pii]
AID - 10.18632/aging.100745 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2015 May;7(5):319-33. doi: 10.18632/aging.100745.